2 nearly penny stocks to buy in September

I’m on a quest to find some of the best cheap UK stocks to buy. Here are a couple of former penny stocks I’d happily buy in September.

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

A lot of UK share investors don’t like to buy cheap companies like penny stocks. Their low cost means that this type of stock is often bought and sold in huge volumes, something that can cause significant price volatility.

I buy stocks for the long term, though. And so the prospect of temporary share price choppiness doesn’t put me off from buying low-cost shares. Here are a couple of top nearly penny stocks I think could soar in value in the years ahead.

The right medicine

The Alliance Pharma (LSE: APH) has risen an impressive 50% during the past 12 months. And in recent sessions this former penny stock has barged to record highs above ÂŁ1. I reckon the business could gain further traction too when half-year results are unveiled on Tuesday, 21 September.

Alliance Pharma owns the marketing rights to scores of heavyweight brands in the fields of consumer healthcare and prescription medicine. These products, like Kelo-Cote scar treatment, Nizoral dandruff shampoo, and (following recent acquisition action) menopause reliever Amberen, sell in huge quantities in more than 100 countries. Indeed, latest financials showed like-for-like sales of its health products up 8% in the six months to June.

Its successful M&A-led growth strategy has helped Alliance Pharma’s earnings rise 33% over the past five years. So I’m encouraged that the stock has plenty of appetite and financial clout to keep going. But acquisitions are risky business and past form is not always a reliable guide to future performance. Revenues from acquisitions can disappoint and costs can swell, taking a big bite out of profits.

A dirt-cheap penny stock I’d buy today

It’s clear that housebuilding activity in the UK needs to ratchet up several gears over the next decade. And this bodes well for manufacturers of building products like Michelmersh Brick Holdings (LSE: MBH). I’ve already bought brickmaker Ibstock for my Stocks and Shares ISA for the very same reason.

I’d buy this nearly penny stock before it releases half-year results on Tuesday, 7 September. Most recent financials in June revealed “strong demand” for its products amid a “very active” construction sector. Many major housebuilders are ramping up production as favourable lending conditions supercharge demand for first-time buyers. So I expect trading at Michelmersh to remain quite robust for some time to come, a theme I don’t think is reflected at current prices. Today the low-cost share trades around 136p, resulting in a forward price-to-earnings growth (PEG) ratio of just 0.5.

I think Michelmersh is a top buy despite the impact that an economic downturn could have on its top line. The UK economy has bounced back strongly following 2020’s Covid-19-related washout. But the rebound could prove temporary and home sales could falter if the Delta variant continues spreading aggressively.

RISK WARNING: should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice. The Motley Fool believes in building wealth through long-term investing and so we do not promote or encourage high-risk activities including day trading, CFDs, spread betting, cryptocurrencies, and forex. Where we promote an affiliate partner’s brokerage products, these are focused on the trading of readily releasable securities.

Royston Wild owns shares of Ibstock. The Motley Fool UK has recommended Alliance Pharma and Ibstock. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Investing Articles

Publish Test

Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut…

Read more »

Investing Articles

JP P-Press Update Test

Read more »

Investing Articles

JP Test as Author

Test content.

Read more »

Investing Articles

KM Test Post 2

Read more »

Investing Articles

JP Test PP Status

Test content. Test headline

Read more »

Investing Articles

KM Test Post

This is my content.

Read more »

Investing Articles

JP Tag Test

Read more »

Investing Articles

Testing testing one two three

Sample paragraph here, testing, test duplicate

Read more »